Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L.

Cell Stem Cell. 2019 Aug 27. pii: S1934-5909(19)30339-X. doi: 10.1016/j.stem.2019.08.004. [Epub ahead of print]

PMID:
31495780
2.

A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.

Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A.

Clin Cancer Res. 2019 Apr 1;25(7):2096-2108. doi: 10.1158/1078-0432.CCR-18-3496. Epub 2018 Dec 20.

PMID:
30573690
3.

IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.

Puig-Saus C, Parisi G, Garcia-Diaz A, Krystofinski PE, Sandoval S, Zhang R, Champhekar AS, McCabe J, Cheung-Lau GC, Truong NA, Vega-Crespo A, Komenan MDS, Pang J, Macabali MH, Saco JD, Goodwin JL, Bolon B, Seet CS, Montel-Hagen A, Crooks GM, Hollis RP, Campo-Fernandez B, Bischof D, Cornetta K, Gschweng EH, Adelson C, Nguyen A, Yang L, Witte ON, Baltimore D, Comin-Anduix B, Kohn DB, Wang X, Cabrera P, Kaplan-Lefko PJ, Berent-Maoz B, Ribas A.

Clin Cancer Res. 2019 Feb 1;25(3):1000-1011. doi: 10.1158/1078-0432.CCR-18-0963. Epub 2018 Nov 8.

PMID:
30409823
4.

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.

Mehta A, Kim YJ, Robert L, Tsoi J, Comin-Anduix B, Berent-Maoz B, Cochran AJ, Economou JS, Tumeh PC, Puig-Saus C, Ribas A.

Cancer Discov. 2018 Aug;8(8):935-943. doi: 10.1158/2159-8290.CD-17-1178. Epub 2018 Jun 13.

5.

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.

Nowicki TS, Escuin-Ordinas H, Avramis E, Chmielowski B, Chodon T, Berent-Maoz B, Wang X, Kaplan-Lefko P, Yang L, Baltimore D, Economou JS, Ribas A, Comin-Anduix B.

J Immunother. 2018 Jun;41(5):248-259. doi: 10.1097/CJI.0000000000000216.

6.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS.

Cell. 2017 Jan 26;168(3):542. doi: 10.1016/j.cell.2017.01.010. No abstract available.

7.

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA Jr, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A.

Cancer Discov. 2017 Feb;7(2):188-201. doi: 10.1158/2159-8290.CD-16-1223. Epub 2016 Nov 30.

8.

Distinct Genetic Networks Orchestrate the Emergence of Specific Waves of Fetal and Adult B-1 and B-2 Development.

Montecino-Rodriguez E, Fice M, Casero D, Berent-Maoz B, Barber CL, Dorshkind K.

Immunity. 2016 Sep 20;45(3):527-539. doi: 10.1016/j.immuni.2016.07.012. Epub 2016 Aug 23.

9.

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A.

N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.

10.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS.

Cell. 2016 Mar 24;165(1):35-44. doi: 10.1016/j.cell.2016.02.065. Epub 2016 Mar 17. Erratum in: Cell. 2017 Jan 26;168(3):542.

11.

The expansion of thymopoiesis in neonatal mice is dependent on expression of high mobility group a 2 protein (Hmga2).

Berent-Maoz B, Montecino-Rodriguez E, Fice M, Casero D, Seet CS, Crooks GM, Lowry W, Dorshkind K.

PLoS One. 2015 May 1;10(5):e0125414. doi: 10.1371/journal.pone.0125414. eCollection 2015.

12.

Proteolytic histone modification by mast cell tryptase, a serglycin proteoglycan-dependent secretory granule protease.

Melo FR, Vita F, Berent-Maoz B, Levi-Schaffer F, Zabucchi G, Pejler G.

J Biol Chem. 2014 Mar 14;289(11):7682-90. doi: 10.1074/jbc.M113.546895. Epub 2014 Jan 29.

13.

Causes, consequences, and reversal of immune system aging.

Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K.

J Clin Invest. 2013 Mar;123(3):958-65. doi: 10.1172/JCI64096. Epub 2013 Mar 1. Review.

14.

Genetic regulation of thymocyte progenitor aging.

Berent-Maoz B, Montecino-Rodriguez E, Dorshkind K.

Semin Immunol. 2012 Oct;24(5):303-8. doi: 10.1016/j.smim.2012.04.006. Epub 2012 May 2. Review.

15.

Fibroblast growth factor-7 partially reverses murine thymocyte progenitor aging by repression of Ink4a.

Berent-Maoz B, Montecino-Rodriguez E, Signer RA, Dorshkind K.

Blood. 2012 Jun 14;119(24):5715-21. doi: 10.1182/blood-2011-12-400002. Epub 2012 May 3.

16.

Influence of FAS on murine mast cell maturation.

Berent-Maoz B, Gur C, Vita F, Soranzo MR, Zabucchi G, Levi-Schaffer F.

Ann Allergy Asthma Immunol. 2011 Mar;106(3):239-44. doi: 10.1016/j.anai.2010.12.001. Epub 2011 Jan 13.

PMID:
21354026
17.

Human mast cells express intracellular TRAIL.

Berent-Maoz B, Salemi S, Mankuta D, Simon HU, Levi-Schaffer F.

Cell Immunol. 2010;262(2):80-3. doi: 10.1016/j.cellimm.2010.02.003. Epub 2010 Feb 6.

PMID:
20189551
18.

Are we ready to downregulate mast cells?

Karra L, Berent-Maoz B, Ben-Zimra M, Levi-Schaffer F.

Curr Opin Immunol. 2009 Dec;21(6):708-14. doi: 10.1016/j.coi.2009.09.010. Review.

PMID:
19837574
19.

Human mast cell activation by Staphylococcus aureus: interleukin-8 and tumor necrosis factor alpha release and the role of Toll-like receptor 2 and CD48 molecules.

Rocha-de-Souza CM, Berent-Maoz B, Mankuta D, Moses AE, Levi-Schaffer F.

Infect Immun. 2008 Oct;76(10):4489-97. doi: 10.1128/IAI.00270-08. Epub 2008 Jul 21.

20.

Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a.

Bachelet I, Munitz A, Berent-Maoz B, Mankuta D, Levi-Schaffer F.

J Immunol. 2008 May 1;180(9):6064-9.

21.

TRAIL mediated signaling in human mast cells: the influence of IgE-dependent activation.

Berent-Maoz B, Salemi S, Mankuta D, Simon HU, Levi-Schaffer F.

Allergy. 2008 Mar;63(3):333-40. doi: 10.1111/j.1398-9995.2007.01598.x. Erratum in: Allergy. 2009 Apr;64(4):666.

PMID:
18269677
22.

Human mast cells undergo TRAIL-induced apoptosis.

Berent-Maoz B, Piliponsky AM, Daigle I, Simon HU, Levi-Schaffer F.

J Immunol. 2006 Feb 15;176(4):2272-8.

Supplemental Content

Loading ...
Support Center